REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., March 2, 2026/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

Leerink Partners Global Healthcare Conference
Fireside Chat: Monday, March 9 at 9:20am ET
Location: Miami, FL

Barclays 28th Annual Global Healthcare Conference
Fireside Chat: Tuesday, March 10 at 1:30pm ET
Location: Miami, FL

RBC Inaugural Virtual Ophthalmology Conference
Fireside Chat: Tuesday, March 24 at 8:45am ET
Location: Virtual

Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at https://www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.

ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit https://WWW.REGENXBIO.COM.

Contacts:
Dana Cormack
Corporate Communications
[email protected]

Investors:
George E. MacDougall
Investor Relations
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302700392.html

SOURCE REGENXBIO Inc.